Colorectal cancer (CRC) is a public health problem: it is the third most common cancer in
men (746,000 new cases/year) and the second in women (614,000 new cases/year) …

Options for Second-Line Treatment in Metastatic Colorectal Cancer Page 1 46 Clinical
Advances in Hematology & Oncology Volume 14, Issue 1 January 2016 Options for Second-Line …

In this review article we discuss the evolution of second-line treatment options for patients
with metastatic colorectal cancer (mCRC). The benefits of second-line chemotherapy have …

Background The optimal chemotherapeutic regimen for use beyond the second line for
patients with metastatic colorectal cancer (mCRC) remains unclear. Materials and methods …

Until recently, treatment options for patients with metastatic colorectal cancer (CRC) were
limited to chemotherapy, vascular endothelial growth factor–targeted therapy, and, for …

Selection of third-line treatment in metastatic colorectal cancer depends on the agents that
have been used in prior therapy. A principle in treatment is to use all five of the active drugs …

Introduction The outcome of patients with metastatic colorectal cancer (mCRC) has
improved significantly in the last few decades. Metastatic colorectal cancer is a highly …

First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in
combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of …

Background The past years' therapy for colorectal cancer has evolved rapidly with the
introduction of novel cytotoxic agents such as irinotecan, capecitabine and oxaliplatin …

Colorectal cancer (CRC) is the third most common cancer in men and the second most
common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56 …